• 1
    Kim RJ, Chen EL, Lima JA, Judd RM. Myocardial Gd-DTPA kinetics determine MRI contrast enhancement and reflect the extent and severity of myocardial injury after acute reperfused infarction. Circulation 1996; 94: 33183326.
  • 2
    Kim RJ, Hillenbrand HB, Judd RM. Evaluation of myocardial viability by MRI. Herz 2000; 25: 417430.
  • 3
    Thomson LE, Kim RJ, Judd RM. Magnetic resonance imaging for the assessment of myocardial viability. J Magn Reson Imaging 2004; 19: 771788.
  • 4
    Wagner A, Mahrholdt H, Holly TA, Elliott MD, Regenfus M, Parker M, Klocke FJ, Bonow RO, Kim RJ, Judd RM. Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study. Lancet 2003; 361: 374379.
  • 5
    Wu E, Judd RM, Vargas JD, Klocke FJ, Bonow RO, Kim RJ. Visualisation of presence, location, and transmural extent of healed Q-wave and non-Q-wave myocardial infarction. Lancet 2001; 357: 2128.
  • 6
    Gottlieb I, Macedo R, Bluemke DA, Lima JA. Magnetic resonance imaging in the evaluation of non-ischemic cardiomyopathies: current applications and future perspectives. Heart Fail Rev 2006; 11: 313323.
  • 7
    Nazarian S, Bluemke DA, Lardo AC, Zviman MM, Watkins SP, Dickfeld TL, Meininger GR, Roguin A, Calkins H, Tomaselli GF, Weiss RG, Berger RD, Lima JA, Halperin HR. Magnetic resonance assessment of the substrate for inducible ventricular tachycardia in nonischemic cardiomyopathy. Circulation 2005; 112: 28212825.
  • 8
    Shehata ML, Turkbey EB, Vogel-Claussen J, Bluemke DA. Role of cardiac magnetic resonance imaging in assessment of nonischemic cardiomyopathies. Top Magn Reson Imaging 2008; 19: 4357.
  • 9
    Wu KC, Weiss RG, Thiemann DR, Kitagawa K, Schmidt A, Dalal D, Lai S, Bluemke DA, Gerstenblith G, Marban E, Tomaselli GF, Lima JA. Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J Am Coll Cardiol 2008; 51: 24142421.
  • 10
    Simonetti OP, Kim RJ, Fieno DS, Hillenbrand HB, Wu E, Bundy JM, Finn JP, Judd RM. An improved MR imaging technique for the visualization of myocardial infarction. Radiology 2001; 218: 215223.
  • 11
    Wagner A, Mahrholdt H, Thomson L, Hager S, Meinhardt G, Rehwald W, Parker M, Shah D, Sechtem U, Kim RJ, Judd RM. Effects of time, dose, and inversion time for acute myocardial infarct size measurements based on magnetic resonance imaging-delayed contrast enhancement. J Am Coll Cardiol 2006; 47: 20272033.
  • 12
    Kim RJ, Albert TS, Wible JH, Elliott MD, Allen JC, Lee JC, Parker M, Napoli A, Judd RM. Performance of delayed-enhancement magnetic resonance imaging with gadoversetamide contrast for the detection and assessment of myocardial infarction: an international, multicenter, double-blinded, randomized trial. Circulation 2008; 117: 629637.
  • 13
    Iles L, Pfluger H, Phrommintikul A, Cherayath J, Aksit P, Gupta SN, Kaye DM, Taylor AJ. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol 2008; 52: 15741580.
  • 14
    Judd RM, Kim RJ. Imaging time after Gd-DTPA injection is critical in using delayed enhancement to determine infarct size accurately with magnetic resonance imaging. Circulation 2002; 106: e6; author reply e6.
  • 15
    Knowles BR, Batchelor PG, Parish V, Ginks M, Plein S, Razavi R, Schaeffter T. Pharmacokinetic modeling of delayed gadolinium enhancement in the myocardium. Magn Reson Med 2008; 60: 15241530.
  • 16
    Weinmann HJ, Laniado M, Mutzel W. Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys Med NMR 1984; 16: 167172.
  • 17
    Tofts PS, Kermode AG. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med 1991; 17: 357367.
  • 18
    Boss A, Martirosian P, Gehrmann M, Artunc F, Risler T, Oesingmann N, Claussen CD, Schick F, Kuper K, Schlemmer HP. Quantitative assessment of glomerular filtration rate with MR gadolinium slope clearance measurements: a phase I trial. Radiology 2007; 242: 783790.
  • 19
    Peters AM. The kinetic basis of glomerular filtration rate measurement and new concepts of indexation to body size. Eur J Nucl Med Mol Imaging 2004; 31: 137149.
  • 20
    Sharma P, Socolow J, Patel S, Pettigrew RI, Oshinski JN. Effect of Gd-DTPA-BMA on blood and myocardial T1 at 1.5T and 3T in humans. J Magn Reson Imaging 2006; 23: 323330.
  • 21
    Weinmann HJ, Bauer H, Ebert W, Frenzel T, Raduchel B, Platzek J, Schmitt-Willich H. Comparative studies on the efficacy of MRI contrast agents in MRA. Acad Radiol 2002; 9( Suppl 1): S135S136.
  • 22
    Larsson HB, Fritz-Hansen T, Rostrup E, Sondergaard L, Ring P, Henriksen O. Myocardial perfusion modeling using MRI. Magn Reson Med 1996; 35: 716726.
  • 23
    Group ER. Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 1999; 22: 99111.
  • 24
    Jacobson AM, Musen G, Ryan CM, Silvers N, Cleary P, Waberski B, Burwood A, Weinger K, Bayless M, Dahms W, Harth J. Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med 2007; 356: 18421852.
  • 25
    American Diabetes Association. Standards of medical care in diabetes-2009. Diabetes Care 2009; 32( Suppl 1): S13S61.
  • 26
    Taylor JR. An introduction to error analysis, 2nd ed. Sausalito, CA: University Science Books; 1997. pp 261271.
  • 27
    Messroghli DR, Plein S, Higgins DM, Walters K, Jones TR, Ridgway JP, Sivananthan MU. Human myocardium: single-breath-hold MR T1 mapping with high spatial resolution—reproducibility study. Radiology 2006; 238: 10041012.
  • 28
    Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998; 9( 12 Suppl): S16S23.
  • 29
    Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32( 5 Suppl 3): S112S119.
  • 30
    Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, Greenland P, Jacob DR Jr, Kronmal R, Liu K, Nelson JC, O'Leary D, Saad MF, Shea S, Szklo M, Tracy RP. Multi-ethnic study of atherosclerosis: objectives and design. Am J Epidemiol 2002; 156: 871881.
  • 31
    Delaney JA, McClelland RL, Brown E, Bluemke DA, Vogel-Claussen J, Lai S, Heckbert SR. Multiple imputation for missing with cardiac magnetic resonance imaging data: results from the Multi-Ethnic Study of Atherosclerosis (MESA). Can J Cardiol 2009; 25: e232E235.
  • 32
    Huppertz A, Rohrer M. Gadobutrol, a highly concentrated MR-imaging contrast agent: its physicochemical characteristics and the basis for its use in contrast-enhanced MR angiography and perfusion imaging. Eur Radiol 2004; 14( Suppl 5): M12M18.
  • 33
    Messroghli DR, Greiser A, Frohlich M, Dietz R, Schulz-Menger J. Optimization and validation of a fully integrated pulse sequence for modified look-locker inversion-recovery (MOLLI) T1 mapping of the heart. J Magn Reson Imaging 2007; 26: 10811086.